Gerasimov Alexandra, Golderman Valery, Gofrit Shany Guly, Aharoni Shay Anat, Zohar Daniela Noa, Itsekson-Hayosh Ze'ev, Fay-Karmon Tsviya, Hassin-Baer Sharon, Chapman Joab, Maggio Nicola, Shavit-Stein Efrat
Department of Neurology, The Chaim Sheba Medical Center, Ramat Gan, Israel.
Department of Neurology and Neurosurgery, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neural Regen Res. 2021 Oct;16(10):2086-2092. doi: 10.4103/1673-5374.308098.
Inflammation and coagulation are tightly interconnected in the pathophysiology of neuronal diseases. Thrombin, a pro-coagulant serine protease is associated with neurodegeneration and its indirect inhibitor, activated protein C (aPC), is considered neuroprotective. While levels of thrombin and aPC activity are readily measured in the blood, similar assays in the cerebrospinal fluid (CSF) have not been described. The aim of this study was to establish a specific and sensitive enzymatic assay to measure both thrombin and aPC activity in the CSF. CSF was collected from 14 patients with suspected normal pressure hydrocephalus served as a control group, while seven patients with central nervous system infections served as an acute neuro-inflammatory study group and one sample of CSF following traumatic lumbar puncture served as a positive control. Thrombin and aPC activities were measured by fluorescence released by specific proteolytic cleavage in the presence of endopeptidase and amino-peptidase inhibitors to ensure specificity. Specificity of the method was verified by thrombin and serine-protease inhibitors N-alpha-((2-naphthylsulfinyl)glycyl)-DL-p-amidinophenylalanylpiperidine and phenylmethanesulfonyl fluoride. Inhibition of thrombin activity by CSF samples and levels of specific thrombin inhibitors were also assessed. Thrombin and aPC activities were reliably measured and were significantly higher in the CSF of patients with central nervous system infections compared to normal pressure hydrocephalus controls, suggesting the involvement of these factors in neuro-inflammation. CSF thrombin activity levels in the presence of known thrombin concentration were high in patients with central nervous system infections, and low in normal pressure hydrocephalus patients. Quantification of endogenous thrombin inhibitors protease nexin 1, amyloid precursor protein and anti-thrombin III in CSF by western blot indicated a significant elevation of amyloid precursor protein in infectious CSF. In conclusion, this study describes a novel and sensitive assay aimed at the detection of thrombin and aPC activity in CSF. This method may be useful for measuring these factors that reflect degenerative and protective influences of coagulation on neurological disorders. The study procedure was approved by the Ethics Committee of the Chaim Sheba Medical Center (approval No. 4245-17-SMC) on October 18, 2018.
在神经疾病的病理生理学中,炎症和凝血紧密相连。凝血酶是一种促凝血丝氨酸蛋白酶,与神经退行性变有关,其间接抑制剂活化蛋白C(aPC)被认为具有神经保护作用。虽然血液中凝血酶水平和aPC活性很容易测量,但脑脊液(CSF)中类似的检测方法尚未见报道。本研究的目的是建立一种特异性和敏感性高的酶法,用于测量脑脊液中凝血酶和aPC的活性。从14例疑似正常压力脑积水患者收集脑脊液作为对照组,7例中枢神经系统感染患者作为急性神经炎症研究组,1例创伤性腰椎穿刺后的脑脊液样本作为阳性对照。在存在内肽酶和氨肽酶抑制剂的情况下,通过特异性蛋白水解切割释放的荧光来测量凝血酶和aPC的活性,以确保特异性。用凝血酶和丝氨酸蛋白酶抑制剂N-α-((2-萘基亚磺酰基)甘氨酰)-DL-p-脒基苯丙氨酰哌啶和苯甲磺酰氟验证了该方法的特异性。还评估了脑脊液样本对凝血酶活性的抑制作用以及特异性凝血酶抑制剂的水平。可靠地测量了凝血酶和aPC的活性,中枢神经系统感染患者脑脊液中的活性显著高于正常压力脑积水对照组,表明这些因素参与了神经炎症。在已知凝血酶浓度的情况下,中枢神经系统感染患者脑脊液中凝血酶活性水平较高,正常压力脑积水患者脑脊液中凝血酶活性水平较低。通过蛋白质印迹法对脑脊液中内源性凝血酶抑制剂蛋白酶连接蛋白1、淀粉样前体蛋白和抗凝血酶III进行定量分析,结果表明感染性脑脊液中淀粉样前体蛋白显著升高。总之,本研究描述了一种用于检测脑脊液中凝血酶和aPC活性的新型敏感检测方法。该方法可能有助于测量这些反映凝血对神经系统疾病的退行性和保护作用的因素。该研究程序于2018年10月18日获得海姆·谢巴医疗中心伦理委员会批准(批准号4245-17-SMC)。